This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Dalhousie University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
BRIGHT Coaching to empower caregivers of children with emerging developmental delays on waitlists for services: A randomized controlled trial.
Developmental medicine and child neurology · 2026
Latest funding
- $4,569,190
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
CIHR · 2023 · Co-investigator
- $1,142,297
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
CIHR · 2023 · Co-investigator
A multi-site examination of vaccine uptake and contributing factors in youth with autism spectrum disorder
CIHR · 2016 · Nominated PI
1 publications.
BRIGHT Coaching to empower caregivers of children with emerging developmental delays on waitlists for services: A randomized controlled trial.
Majnemer A, Ogourtsova T, O'Donnell M, Wittmeier K, Filliter J, Batara J, Yaskina M, BRIGHT Coaching Parent Advisory Group, BRIGHT Coaching Study Group
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
Principal investigators: Halperin, Scott A; Ward, Brian J
Keywords: Challenge Study; Challenge Unit; Controlled Human Infection Model (Chim); Dose-Finding; Dose-Ranging; Healthy Adults; Influenza Virus; Pandemic Preparedness; Phase 1/2 Clinical Trial
Open-label, phase 1/2, dose-escalation and dose-confirmation clinical trial to establish a Controlled Human Infection Model (CHIM) by determining and confirming the optimal, safe, and reproducible Influenza A:H3N2 dose administered intranasally to healthy adults 18-40 years of age that induces mild symptomatic infection and detection of Influenza A:H3N2 in nasal secretions by culture and/or PCR
Principal investigators: Halperin, Scott A; Ward, Brian J
Keywords: Challenge Study; Challenge Unit; Controlled Human Infection Model (Chim); Dose-Finding; Dose-Ranging; Healthy Adults; Influenza Virus; Pandemic Preparedness; Phase 1/2 Clinical Trial
A multi-site examination of vaccine uptake and contributing factors in youth with autism spectrum disorder
Principal investigators: Filliter, Jillian H; Macdonald, Nora (Noni) E; Robinson, Joan L; Dodds, Linda; Kaul, Padmaja R
Keywords: Autism; Autism Spectrum Disorder; Context; Database Linkage; Focus Groups; Mixed Methods; Multi-Site Study; Public Health; Vaccination; Vaccine Hesitancy
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Pediatrics
- Neurology
- Pediatrics and Child Health
Co-authors at Dalhousie University, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.